Welcome to BioSeeker Group!

Triple Analysis: Breast Cancer, Leukemia and Lung Cancer

Additional Information

Published Date Aug 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4225
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Breast Cancer, Leukemia and Lung Cancer in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Lung Cancer.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Leukemia and Lung Cancer.

    To find out more about Triple Analysis: Breast Cancer, Leukemia and Lung Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Leukemia and Lung Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Leukemia and Lung Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer
The breast cancer drug report part comprises defined and up to date development strategies for 470 drugs within the portfolio of 247 companies world-wide, from Ceased to Marketed. The report extensively analyses their 234 identified drug targets, organized into 223 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part III: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer
5.1 The Scope of this Report 32
6 Consider the Therapeutic Target Among Breast Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (234 Drug Targets) 36-522
7 Emerging New Products to Established Ones: Drug Target Strategies of Breast Cancer Drugs by their Highest Stage of Development (223 Drug Target Strategies and 470 Drugs) 523-797
8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Compound Strategies) 798-850
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Breast Cancer Drug Pipeline by Investigator (247 Investigators and 470 Drugs) 851-1723
10 Disclaimer 1724
Figures: Includes 8 Figures
Tables: Includes 309 Tables
Total Number of Pages: 1,755

Part II: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part III: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
A&G Pharmaceutical
Abbott
Abiogen
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Alfa Wassermann
Allos Therapeutics
Alnis Biosciences
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Amgen
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
ApopLogic Pharmaceuticals
Apotex
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascend Therapeutics
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Basilea Pharmaceutica
Bavarian Nordic
Bayer
Benitec
Beta Pharma
Betagenon
Betapharma
Bio-Path Holdings
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioLineRx
BioMarin
Bionovo
BioNumerik
BioSante
Biotecnol
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
CanBas
Cancer Research Technology
Cel-Sci
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiesi
Chong Kun Dang
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
CLL Pharma
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Domainex
Dong-A
Dongkook Pharm
Douglas
ECI
Eisai
Elara Pharmaceuticals
Eleos
ElexoPharm
Eli Lilly
Emergent BioSolutions
Endoceutics
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Eucodis
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Formula Pharmaceuticals
Fresenius
Galapagos
Galectin Therapeutics
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
GlycoMimetics
GlyTag
Got-a-Gene
Gradalis
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Heidelberg Pharma
Hoffmann-La Roche
Hospira
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intarcia Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
KaloBios
Kanisa
Kiadis
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Memgen
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MetaMol Theranostics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NexGenix Pharmaceuticals
Nidus Laboratories
NIH
Nimbus Discovery
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
Novartis
Novogen
Oasmia
OncoGenex Pharmaceuticals
Oncolix
OncoMed
OncoMune
Onconova
Oncothyreon
Oncozyme Pharma
Orchestra Therapeutics
Orion Pharma
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Pantarhei Bioscience
PBL Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PheneX
Philogen
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Pro-Pharmaceuticals
Prochon Biotech
Progen Pharmaceuticals
ProMetic Life Sciences
ProStrakan
PTC Therapeutics
R&R
Radient Pharmaceuticals
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Samyang
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
Savient Pharmaceuticals
SBI Biotech
SBIO
Schering-Plough
Seattle Genetics
SEEK
Selvita
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
ShimodaAtlantic Oncology
Shire
Sidus
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Southern Research Institute
Spirogen
SRI International
Stemline Therapeutics
Sun Pharma Advanced Research
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Taiwan Liposome Company
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
Taxolog
TeGenero
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
Vaccinex
Valeant
Vaxon Biotech
VaxOnco
Verastem
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
ViroMed
ViroTarg
Wyeth
XBiotech
Xencor
Xerion
Xoma
Yakult Honsha
Yamasa Corporation
YM BioSciences
Zensun
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
Zydus Cadila
A Shortlist of Drugs Included are:
177-Lu-AMBA
17ß-hydroxysteroid dehydrogenase-1 inhibitors
2-methoxyestradiol
2aG4-IL-2 fus protein + PS MAb
4-hydroxytamoxifen
5-FU
852A
9-aminocamptothecin
AB-16B5
abiraterone acetate
ABT-510
ACC inhibitor
acolbifene
adecatumumab
aderbasib
Adva-27a
AE-37
AEE-788
AEG-35156
AEZS-108
afatinib
aflibercept
AFM-21
AG-1
agatolimod
aglycon protopanaxadiol
alemtuzumab
alvespimycin hydrochloride
alvocidib
amatuximab
AMG-386
amonafide dihydrochloride
amonafide malate
amrubicin hydrochloride
amsacrine
amuvatinib
anastrozole
androgen receptor antagonist
angiopep+paclitaxel
Angiozyme
annamycin
anti-C35 MAb
anti-HER-2/neu antisense
anti-HER2 MAb
anti-HER2neu scFv
anti-Hsp90-alpha MAbs
anti-PCDGF MAbs
anticancers
antiestrogen
apricoxib
AR-002
AR-004
AR-7BD-33-11A
ARC-100
ARQ-197
ARQ-621
ARRY-380
arzoxifene hydrochloride
AS-1402
ASP-08126
astuprotimut-r
atamestane
ATN-224
atrasentan
Auto TAG vaccine
AUY-922
AVE-1642
AVI-4126
avorelin
AVX-701
axitinib
AZD-1480
AZD-4547
AZD-4877
AZD-4992
AZD-8931
BAL-27862
banoxantrone
barasertib
becatecarin
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
BEZ-235
BGT-226
BIBF-1120
bisantrene
BIW-8556
BMN-673
BMS-599626
BMS-690514
BMS-753493
BMS-754807
BN-107
bortezomib
bosutinib
brca2
breast cancer therapy
breast cancer vaccine
BreMel/TNF-alpha
BrevaRex MAb
brivanib alaninate
brivudine
BZL-101
CAB-051
Cabozantinib
cancer therapy (1)
cancer therapy (2)
canertinib dihydrochloride
canfosfamide hydrochloride
capecitabine
carbetocin
catumaxomab
CDX-1307
CEA cancer vaccine
cediranib
celecoxib
cetuximab
CGX-0682
CH-4986399
CHF-4227
cilengitide
cixutumumab
cladribine
clofarabine
CNF-2024
contusugene ladenovec
CP-724714
crizotinib
crolibulin
CSF-GM
CTCE-9908
CTP-37
CUDC-101
custirsen
CVac
CX-4945
CYN-101
cytarabine ocfosfate
cytarabine, injectable
D-3263
dabigatran etexilate
dacomitinib
dalotuzumab
dasatinib
daunorubicin
decitabine
denosumab
Diflomotecan
dinaciclib
docetaxel
docetaxel (1)
docetaxel (2)
docetaxel (3)
docetaxel (4)
docetaxel (5)
docetaxel MAb
dovitinib lactate
doxifluridine
doxorubicin (1)
doxorubicin (10)
doxorubicin (11)
doxorubicin (2)
doxorubicin (3)
doxorubicin (4)
doxorubicin (5)
doxorubicin (6)
doxorubicin (7)
doxorubicin (8)
doxorubicin (9)
doxorubicin citrate
DXL-702
E-75
E39
ECI-301
elacytarabine
elomotecan
elsamitrucin
emepepimut-S
endostatin
endoxifen
eniluracil
enocitabine
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
epothilone D
erlotinib
ERR antagonists
ertumaxomab
estetrol
estrogen inhibitors
etoposide (1)
etoposide phosphate
everolimus
exatecan mesylate
exemestane
Exherin
exisulind
EZH2
F16-IL2
fadrozole
FASN inhibitors
figitumumab
flt-4 kinase inhibitors
formestane (1)
formestane (2)
fosfluridine tidoxil
FPI-01
fulvestrant
fusion toxins
Galactomycin-UCLT
galarubicin hydrochloride
ganitumab
gataparsen
GDC-0980
gefitinib
gemtuzumab ozogamicin
gimatecan
glembatumumab vedotin
GlyB4
golnerminogene pradenovec
goserelin
goserelin acetate ER
GPR40 antagonists
GSK-1059615
GSK-2130579A
GSK-2302024A
GVAX
HAS2 inhibitor
HE-3235
Her-2/Neu peptides
HER2 vaccine
her2/neu antigen
Her2/neu gene therapy
histamine dihydrochloride
huBrE-3 tiuxetan
HuMax-Her2
HuMax-VEGF
icotinib hydrochloride
icrucumab
idarubicin
idronoxil
IGF-1 receptor inhibitor
IGN-101
IKKe/TBK1 inhibitor
imatinib mesilate
imetelstat
IMGN-388
immunogene therapy
IMO-2055
IMP-321
Imuteran
INCB-028060
indisulam
ING-1
ingenol mebutate
INGN-225
INGN-241
inherbins
iniparib
INNO-206
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon (gamma1b)
interferon (ß1a)
interferon alpha-2b
interleukins
IPH-3102
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
JMR-132
KW-2170
KX2-391
labetuzumab
labetuzumab-SN-38
lapatinib ditosylate
lapuleucel-T
larotaxel
lasofoxifene
lenvatinib
leptin antagonists
lestaurtinib
letrozole
leucine-doxorubicin
leukemia vaccine
leuprorelin
linifanib
linsitinib
LipoVIL12
lonafarnib
lonaprisan
LOR-2040
Lovaxin B
lumiliximab
LY-2157299
MAGH-22
MDX-1140
ME-103
MEDI-547
Mesd-based peptides
MetXia
MGN-1601
MGN-1703
midostaurin
milataxel
mitoxantrone
MK-2206
MKC-1
MLN-8237
MM-111
MM-121
MORAb-004
motesanib diphosphate
motexafin gadolinium
MP-529
MS-209
MT-110
MUC-1 vaccine
MVA-BN Her-2 vaccine
Nab-docetaxel
nadroparin
necitumumab
neratinib
nilotinib
nimotuzumab
NK-012
NL-0031
nolatrexed dihydrochloride
NXD-30001
OB-cadherin antibodies
obinutuzumab
oblimersen sodium
OCM-111
OCM-8054
OCM-8224
ofatumumab
OGX-225
OGX-427
olaparib
ON-01910
ON-045270
onartuzumab
Onco-L TCS
oncolytic viruses
OSI-7904L
osteolytic disease therapy
Osteopontin-c inhibitor


P276-00
paclitaxel
paclitaxel (1)
paclitaxel (10)
paclitaxel (11)
paclitaxel (12)
paclitaxel (13)
paclitaxel (14)
paclitaxel (2)
paclitaxel (3)
paclitaxel (4)
paclitaxel (5)
paclitaxel (6)
paclitaxel (7)
paclitaxel (8)
paclitaxel (9)
paclitaxel polyglumex
paclitaxel-DHA
PankoPep
panobinostat
PANVAC-VF
patupilone
pazopanib hydrochloride
PD-0325901
PD-0332991
peginterferon alfa-2b
pelitinib
pemetrexed disodium
pentamidine isethionate
pentostatin
peptidomimetics
perifosine
pertuzumab
PhG-alpha-1
pixantrone
PKI-179
PKI-587
pralatrexate
Prolanta
Prolanta ER
prostate cancer therapy
PRX-321
PSK-3668
PTC-299
PX-104.1
R-763
radiotherapeutic
raloxifene hydrochloride
ramucirumab
razoxane
retaspimycin
Reximmune-C
Rexin-G
RG-1507
RG-7321
rhErbB3-f
rhIFN-alpha
ridaforolimus
rinfabate
rituximab
romidepsin
RR-310
rubitecan
S1P3 inhibitor
sabarubicin
sagopilone
SAR-566658
saracatinib
SBC-202
Sch-57050
SEL-24-1
seliciclib
selumetinib
semaxanib
seocalcitol
SERM + toxin
SF-1126
simotaxel
sipuleucel-T
siRNA gp96 therapy
SM3
SN-38 (1)
SN-38 (2)
SNG-163
SNG-8023
SNG-8038
sobuzoxane
sorafenib tosylate
SPC-2968
SR-13668
SR-16157
SR-31747
ß-lapachone
STA-9090
steroid sulfatase inhibitor
STP-503
SU-14813
SU-6668
sunitinib malate
survivin-2B
Symadex
talactoferrin alfa
talminogene laherparepvec
tamibarotene
tamoxifen (1)
tamoxifen (2)
tamoxifen, oral liquid
tanespimycin
tariquidar
TAS-108
tegafur + uracil
telomerase vaccine
temsirolimus
Tenarad
teniposide
TG-4010
thiocoraline
thymalfasin
thymectacin
tipifarnib
tivozanib
TLK-58130
TLN-4601
TNF + paclitaxel
TNF-alpha
topotecan
toremifene citrate
trastuzumab (1)
trastuzumab (2)
trastuzumab (3)
trastuzumab emtansine
trastuzumab-MMAE conjugate
tremelimumab
triapine
triciribine phosphate
trilostane
triptorelin pamoate
TroVax
TS-1
TTL-2019
TTL-3101
UCN-01
V-930
V935
vandetanib
varlitinib
vatalanib
veliparib
vismodegib
VM-206
vosaroxin
VS-4718
VS-507
VS-5095
VX-001
WX-671
WX-UK1
XL-147
XL-647
XL-765
Y-90-labetuzumab
YM-155
Zemab
zibotentan
zorubicin
ZYC-300

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Breast Cancer, Leukemia and Lung Cancer.
    To find out more about Triple Analysis: Breast Cancer, Leukemia and Lung Cancer, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Breast Cancer, Leukemia and Lung Cancer is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lung Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Apoptosis. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


VEGF Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 253 companies plus partners who are today developing 348 VEGF signaling pathway targeting drugs in 1433 developmental projects in cancer across 164 different targets. In addition, there are 3 suspended drugs and another 151 drugs where development has been ceased. Learn More


Large Pharma:2004 a year of Progress
BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. Learn More